These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26742637)

  • 1. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
    Harrison IF; Anis HK; Dexter DT
    Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
    Harrison IF; Crum WR; Vernon AC; Dexter DT
    Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
    Harrison IF; Powell NM; Dexter DT
    J Neurochem; 2019 Jan; 148(1):136-156. PubMed ID: 30269333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
    Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
    Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.
    Inden M; Kondo J; Kitamura Y; Takata K; Nishimura K; Taniguchi T; Sawada H; Shimohama S
    J Pharmacol Sci; 2005 Feb; 97(2):203-11. PubMed ID: 15684568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
    Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.
    Ferraz AC; Xavier LL; Hernandes S; Sulzbach M; Viola GG; Anselmo-Franci JA; Achaval M; Da Cunha C
    Brain Res; 2003 Oct; 986(1-2):200-5. PubMed ID: 12965246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
    Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
    Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
    Vernon AC; Johansson SM; Modo MM
    BMC Neurosci; 2010 Jan; 11():1. PubMed ID: 20051106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
    Konieczny J; Jantas D; Lenda T; Domin H; Czarnecka A; Kuter K; Śmiałowska M; Lasoń W; Lorenc-Koci E
    Neurotox Res; 2014 Oct; 26(3):255-73. PubMed ID: 24842651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
    Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
    Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective increase of in vivo firing frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain.
    Subramaniam M; Kern B; Vogel S; Klose V; Schneider G; Roeper J
    Eur J Neurosci; 2014 Sep; 40(6):2898-909. PubMed ID: 25059097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
    Elson JL; Yates A; Pienaar IS
    Brain Struct Funct; 2016 May; 221(4):2319-41. PubMed ID: 25989851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
    Zhang X; Xie W; Qu S; Pan T; Wang X; Le W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):544-9. PubMed ID: 15950935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifedipine and nimodipine protect dopaminergic substantia nigra neurons against axotomy-induced cell death in rat vibrosections via modulating inflammatory responses.
    Daschil N; Humpel C
    Brain Res; 2014 Sep; 1581():1-11. PubMed ID: 25038562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.